BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17347845)

  • 1. The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49.
    Norman RP; Evans DG; Easton DF; Young KC
    Eur J Health Econ; 2007 Jun; 8(2):137-44. PubMed ID: 17347845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
    Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
    BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
    Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.
    Lee JM; McMahon PM; Kong CY; Kopans DB; Ryan PD; Ozanne EM; Halpern EF; Gazelle GS
    Radiology; 2010 Mar; 254(3):793-800. PubMed ID: 20177093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
    Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
    BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
    Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.
    Obdeijn IM; Heijnsdijk EA; Hunink MG; Tilanus-Linthorst MM; de Koning HJ
    Eur J Cancer; 2016 Aug; 63():135-42. PubMed ID: 27318001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of costs and benefits of breast cancer screening with mammography, ultrasonography, and MRI.
    Feig S
    Obstet Gynecol Clin North Am; 2011 Mar; 38(1):179-96, ix. PubMed ID: 21419333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of breast magnetic resonance imaging to screen BRCA1/2 mutation carriers.
    Crystal P
    JAMA; 2006 Dec; 296(22):2681-2; author reply 2682. PubMed ID: 17164453
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
    Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J
    J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
    Lee JM; Kopans DB; McMahon PM; Halpern EF; Ryan PD; Weinstein MC; Gazelle GS
    Radiology; 2008 Mar; 246(3):763-71. PubMed ID: 18309013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
    Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
    Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a genetic test for breast cancer risk.
    Folse HJ; Green LE; Kress A; Allman R; Dinh TA
    Cancer Prev Res (Phila); 2013 Dec; 6(12):1328-36. PubMed ID: 24309564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.